Prevalence of unconfirmed positive and confirmed positive Neisseria gonorrhoeae in participants aged 16–44 years, by sex
| Men | Women | |||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Unconfirmed Positive* | Confirmed Positive† | Denominator‡ | Unconfirmed Positive* | Confirmed Positive† | Denominator‡ | |||||||||
| n | Per cent | 95% CI | n | Per cent | 95% CI | Unweighted, weighted | n | Per cent | 95% CI | n | Per cent | 95% CI | Unweighted, weighted | |
| All | 7 | 0.3 | (0.1 to 0.6) | 2 | <0.1 | (0.0 to 0.1) | 1885, 2266 | 14 | 0.5 | (0.3 to 1.0) | 3 | <0.1 | (0.0 to 0.1) | 2665, 2284 |
| Age group | ||||||||||||||
| 16–19 | 3 | 0.9 | (0.3 to 3.0) | 0 | 0.0 | – | 343, 234 | 1 | 0.2 | (0.0 to 1.4) | 0 | 0.0 | – | 395, 214 |
| 20–24 | 1 | 0.1 | (0.0 to 0.8) | 1 | 0.1 | (0.0 to 0.6) | 497, 391 | 5 | 0.8 | (0.3 to 2.2) | 3 | 0.2 | (0.1 to 0.7) | 597, 383 |
| 25–34 | 3 | 0.4 | (0.1 to 1.3) | 1 | 0.1 | (0.0 to 0.4) | 693, 807 | 5 | 0.4 | (0.2 to 1.1) | 0 | 0.0 | – | 1146, 809 |
| 35–44 | 0 | 0.0 | – | 0 | 0.0 | – | 352, 835 | 3 | 0.5 | (0.2 to 1.8) | 0 | 0.0 | – | 527, 878 |
| No. of partners without a condom, past year | ||||||||||||||
| 0 | 3 | 0.5 | (0.1 to 1.5) | 0 | 0.0 | – | 425, 494 | 2 | 0.2 | (0.0 to 0.8) | 0 | 0.0 | – | 469, 428 |
| 1 | 3 | 0.1 | (0.0 to 0.4) | 0 | 0.0 | – | 1111, 1486 | 10 | 0.6 | (0.3 to 1.3) | 0 | 0.0 | – | 1806, 1629 |
| 2+ | 1 | 0.6 | (0.1 to 4.0) | 2 | 0.3 | (0.1 to 1.2) | 322, 264 | 2 | 0.4 | (0.1 to 1.7) | 3 | 0.4 | (0.0 to 0.1) | 355, 200 |
| Co-infection in urine | ||||||||||||||
| Chlamydia (men & women)§ | 0 | 0.0 | – | 4 | 1.9 | (0.7 to 5.1) | 98, 58 | |||||||
| HR-HPV | 0 | 0.0 | – | 1 | 0.2 | (0.0 to 0.6) | 164, 183 | 2 | 0.4 | (0.1 to 1.6) | 3 | 0.2 | (0.0 to 1.2) | 527, 348 |
| Any HPV | 2 | 0.4 | (0.1 to 1.9) | 2 | 0.2 | (0.1 to 0.9) | 323, 354 | 5 | 0.6 | (0.2 to 1.8) | 3 | 0.1 | (0.0 to 0.4) | 959, 673 |
| Experienced urethral symptoms, past month | ||||||||||||||
| No | 7 | 0.3 | (0.1 to 0.6) | 1 | <0.1 | (0.0 to 0.2) | 1781, 2160 | 12 | 0.5 | (0.2 to 1.0) | 3 | <0.1 | (0.0 to 0.1) | 2436, 2105 |
| Yes | 0 | 0.0 | – | 1 | 0.3 | (0.0 to 2.1) | 102, 101 | 2 | 0.9 | (0.2 to 4.3) | 0 | 0.0 | - | 223, 175 |
| Attended sexual health clinic, past 5 years | ||||||||||||||
| No | 4 | 0.2 | (0.1 to 0.6) | 1 | <0.1 | (0.0 to 0.2) | 1328, 1790 | 8 | 0.5 | (0.2 to 1.1) | 1 | <0.1 | (0.0 to 0.1) | 1852, 1766 |
| Yes | 3 | 0.5 | (0.2 to 1.6) | 1 | <0.1 | (0.0 to 0.5) | 526, 439 | 6 | 0.6 | (0.3 to 1.5) | 2 | 0.1 | (0.0 to 0.5) | 788, 499 |
*Unconfirmed positive is a sample with a positive or equivocal dual NAAT result that was negative on two supplementary tests.
†Confirmed positive is a sample with a positive or equivocal dual NAAT result that was positive on at least one of three supplementary tests.
‡Denominator is Natsal-3 participants aged 16–44 years who reported at least one partner, ever.
§For chlamydia, men and women were combined because the denominators were too small for data to be reported by gender separately.
HR-HPV, high risk human papilloma virus; NAAT, nucleic acid amplification test.